Valuation : Ipsen

Market Cap 13.37B 15.53B 12.56B 11.46B 21.53B 1,478B 21.69B 149B 57.89B 749B 58.32B 57.05B 2,481B P/E 2026 *
13.6x
P/E 2027 * 13.9x
Enterprise Value 12.13B 14.09B 11.39B 10.4B 19.54B 1,341B 19.68B 135B 52.53B 680B 52.92B 51.77B 2,252B EV / Sales 2026 *
2.67x
EV / Sales 2027 * 2.39x
Free-Float
40.65%
Yield 2026 *
0.94%
Yield 2027 * 0.94%
1 day-3.78%
1 week+0.25%
Current month-5.30%
1 month-5.30%
3 months+6.41%
6 months-1.21%
Current year+37.07%
1 week 162.7
Extreme 162.7
169.1
1 month 153.8
Extreme 153.8
169.1
Current year 116.5
Extreme 116.5
172.7
1 year 110.9
Extreme 110.9
172.7
3 years 90.2
Extreme 90.2
172.7
5 years 77.76
Extreme 77.76
172.7
10 years 36.84
Extreme 36.84
172.7
Manager TitleAgeSince
Chief Executive Officer 59 2020-06-30
Chief Executive Officer 57 2019-12-31
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 61 2005-08-29
Chairman 68 2010-11-21
Director/Board Member 69 2012-05-31
Change 5-day change 1-year change 3-year change Capi.($)
-3.78%+0.25% - - 15.52B
-1.52%-7.23%+57.34%+108.72% 1,047B
-0.82%-2.63%+49.30%+64.43% 646B
+0.37%-3.06%+21.00%+74.48% 451B
-1.64%-4.75%+35.59%+35.54% 355B
-0.39%-2.76%+21.39%+38.01% 291B
-1.19%-2.21%+1.53%+11.51% 252B
-0.59%-3.15%+49.83%+67.70% 234B
-1.05%-2.29%-19.91%-54.10% 203B
+0.45%-0.27%+29.84%+91.34% 181B
Average -1.00%-2.68%+27.32%+48.63% 406.59B
Weighted average by Cap. -0.79%-3.46%+36.51%+64.77%

Financials

2026 *2027 *
Net sales 4.54B 5.28B 4.27B 3.89B 7.32B 502B 7.37B 50.55B 19.67B 255B 19.81B 19.38B 843B 4.64B 5.39B 4.35B 3.97B 7.47B 512B 7.52B 51.59B 20.07B 260B 20.22B 19.78B 860B
Net income 1.01B 1.17B 949M 866M 1.63B 112B 1.64B 11.25B 4.38B 56.64B 4.41B 4.31B 188B 985M 1.14B 925M 845M 1.59B 109B 1.6B 10.96B 4.27B 55.22B 4.3B 4.2B 183B
Net Debt -1.24B -1.44B -1.16B -1.06B -1.99B -137B -2.01B -13.77B -5.36B -69.37B -5.4B -5.28B -230B -2.3B -2.67B -2.16B -1.97B -3.7B -254B -3.73B -25.58B -9.95B -129B -10.03B -9.81B -427B
Logo Ipsen
Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows: - oncology (69.2%); - neuroscience (20.3%); - rare diseases (10.5%). At the end of 2025, the group had 7 research and development centers located in France (2), the United Kingdom (2), China (2) and Ireland, and 5 manufacturing sites worldwide. Net sales are distributed geographically as follows: France (8%), Europe (31.7%), the United States (32.9%), North America (2.2%) and other (25.2%).
Employees
5,535
Date Price Change
26-08-31 162.70 -3.78%
26-08-28 €169.10 +1.99%
26-08-27 €165.80 +0.18%
26-08-26 €165.50 +0.73%
26-08-25 €164.30 +1.23%
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
163.10EUR
Average target price
167.07EUR
Spread / Average Target
+2.43%

Quarterly revenue - Rate of surprise